Propranolol therapy for Tardive dyskinesia: A retrospective examination

Parkinsonism and Related Disorders

Volumn 32, Issue , 2016, Pages 124-126

  Hatcher Martin, Jaime M ^a   Armstrong, Karen A ^a   Scorr, Laura M ^a   Factor, Stewart A ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Propranolol; Tardive dyskinesia; Tardive dystonia; Therapy

Indexed keywords

PROPRANOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOTENSION; MALE; NIGHTMARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; AGED; FOLLOW UP; MIDDLE AGED; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPRANOLOL; RETROSPECTIVE STUDIES; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 84994766849     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.09.004     Document Type: Article

References (15)

1. [1] Cloud, L.J., Zutshi, D., Factor, S.A., Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics 11 (2014), 166–176.
2. [2] Samie, M.R., Dannenhoffer, M.A., Rozek, S., Life-threatening tardive dyskinesia caused by metoclopramide. Mov. Disord. 2 (1987), 125–129.
3. [3] Zutshi, D., Cloud, L.J., Factor, S.A., Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinetic Mov., 4, 2014, 266.
4. [4] Olfson, M., Blanco, C., Liu, S.M., Wang, S., Correll, C.U., National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch. Gen. Psychiatry 69 (2012), 1247–1256.
5. [5] Silvestri, S., Seeman, M.V., Negrete, J.C., et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacol. Berl. 152 (2000), 174–180.
6. [6] O'Brien, C.F., Jimenez, R., Hauser, R.A., et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov. Disord. 30 (2015), 1681–1687.
7. [7] Factor, S.A., Propranolol therapy for tardive dyskinesia revisited. Mov. Disord., 27, 2012, 1703.
8. [8] Bhide, N., Lindenbach, D., Barnum, C.J., George, J.A., Surrena, M.A., Bishop, C., Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat. J. Neurochem. 134 (2015), 222–232.
9. [9] Bacher, N.M., Lewis, H.A., Low-dose propranolol in tardive dyskinesia. Am. J. Psychiatry 137 (1980), 495–497.
10. [10] Schrodt, G.R. Jr., Wright, J.H., Simpson, R., Moore, D.P., Chase, S., Treatment of tardive dyskinesia with propranolol. J. Clin. Psychiatry 43 (1982), 328–331.
11. [11] Pitts, F.N. Jr., Treatment of tardive dyskinesia with propranolol. J. Clin. Psychiatry, 43, 1982, 304.
12. [12] Silver, J.M., Yudofsky, S.C., Kogan, M., Katz, B.L., Elevation of thioridazine plasma levels by propranolol. Am. J. Psychiatry 143 (1986), 1290–1292.
13. [13] Marino, M.R., Dey, M., Garg, D.C., et al. Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation. J. Clin. Pharmacol. 27 (1987), 885–891.
14. [14] Cleeves, L., Findley, L.J., Propranolol and propranolol-LA in essential tremor: a double blind comparative study. J. Neurol. Neurosurg. Psychiatry 51 (1988), 379–384.
15. [15] Parker, J.O., Porter, A., Parker, J.D., Propranolol in angina pectoris. Comparison of long-acting and standard-formulation propranolol. Circulation 65 (1982), 1351–1355.